Navigation Links
Assurex Health Announces International Expansion through Canadian Partnership with the Centre for Addiction and Mental Health
Date:11/19/2013

MASON, Ohio, Nov. 19, 2013 /PRNewswire/ -- Assurex Health, a leading personalized medicine company focused on neuropsychiatric disorders, today announced the company's first public-private partnership with the Centre for Addiction and Mental Health (CAMH), one of the world's leading research centers in the area of addiction and mental health and Canada's largest mental health teaching hospital.  This joint venture forms AssureRx Canada, Ltd., marking the first international expansion for Assurex Health.  The venture expands the use of GeneSight®, a personalized medicine technology that analyzes a patient's DNA to provide clinicians with an individualized report to help select appropriate treatments for depression, anxiety, bipolar, schizophrenia, ADHD, and chronic pain.

(Logo:  http://photos.prnewswire.com/prnh/20130910/CL75944LOGO)

This partnership has the potential to help millions of Canadians with mental illness avoid trial and error medication prescribing, which is an unfortunate reality for many patients.  Recent studies show that only 30% of patients are prescribed a genetically appropriate medication the first time. This is costly to the health care system and to patients who suffer lost productivity, higher absenteeism, and family/relationship issues. With up to 60 million people in the US and Canada taking a psychotropic, ADHD, or analgesic medication, the North American neuropsychiatric pharmacogenomics market is estimated to be in excess of $4 billion.

Assurex Health has a proven track record in the U.S. with its GeneSight panel, a test reimbursed by a number of insurance companies as well as Medicare and Medicaid. In the U.S., Assurex Health data shows a 70% improvement in depressive symptoms when GeneSight testing is used to predict patient response to antidepressants, and a 28% reduction in health care costs. 

"We are thrilled about our collaboration with CAMH and the opportunity to combine our leading pharmacogenomics technology to serve the Canadian market," said James S. Burns, CEO of Assurex Health. "CAMH is a global thought leader in mental health research and treatment. CAMH discoveries will further enhance our GeneSight products, aiding medication selection and augmenting patient responses to antidepressant and antipsychotic medications. We look forward to working together to help the millions of mental health patients who desire better treatment outcomes," said Burns.

AssureRx Canada has been established as a subsidiary of Assurex Health, with equity ownership by CAMH and Assurex Health, including a Canadian office in Toronto and a certified clinical lab on CAMH premises. A key initial priority of the collaboration includes GeneSight testing of 20,000 Ontario patients for the purpose of improving patient treatment outcomes and reducing mental health care costs in the Province of Ontario. Further objectives include test validation and clinical studies to enhance GeneSight with new genetic markers discovered by CAMH. These include markers to predict which individuals will experience rapid weight gain after taking anti-psychotic medications, a side effect that impacts many patients.  Through this partnership, CAMH will continue research and discovery into genetic markers with AssureRx Canada retaining exclusive rights to commercialize these discoveries globally. The combination of Assurex Health's development and delivery expertise with CAMH's research expertise ensures that progress in this area of personalized medicine will continue to grow for U.S. and Canadian mental health patients.

"This unique partnership combines CAMH's research discoveries of genetic markers with Assurex Health's expertise in developing, validating and bringing new psychiatric pharmacogenomics markers to market," said Dr. Catherine Zahn, MD, President and CEO, CAMH. "We believe that this collaboration will promote the use of personalized medicine in psychiatry to help both doctors and patients experience a smoother process and improve health care for Canadians who need medications for mental health disorders."

About Assurex Health

Assurex Health is a personalized medicine company that specializes in pharmacogenomics and is dedicated to helping physicians determine the right medication for individual patients with neuropsychiatric and other disorders. The company was founded to commercialize industry-leading personalized medicine technology for neuropsychiatric disorders. Assurex Health has licensed technology from Mayo Clinic and Cincinnati Children's Hospital Medical Center.

For more information about Assurex Health, please visit www.assurexhealth.com.

About GeneSight

GeneSight is a laboratory-developed pharmacogenomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSight report can help a clinician understand the way a patient's unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual's response to drug treatments, manufacturers' FDA approved drug labels, peer reviewed scientific and clinical publications, and proven drug pharmacology.  Quick turnaround time, combined with a customized report of the patient's genomic makeup, clinical experience, and other factors can provide information to help a physician make personalized drug treatment choices for each patient.

About CAMH 

The Centre for Addiction and Mental Health (CAMH) is Canada's largest mental health and addiction teaching hospital, and one of the world's leading research centers in this field. CAMH combines clinical care, research, education, policy development and health promotion to help transform the lives of people affected by mental illness and addiction. CAMH is fully affiliated with the University of Toronto, and is a Pan American Health Organization/World Health Organization Collaborating Centre. ​​

Registered trademarks are the property of their respective owners.


'/>"/>
SOURCE Assurex Health
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Assurex Health Appoints Veteran P&G Consumer Products Executive Virginia Coleman Drosos President to Lead Personalized Medicine Growth
2. Assurex Health Appoints Chief Financial Officer and Payer Market Executive to Manage Rapid Growth in Personalized Medicine
3. As Affordable Care Act Sputters out of the Gate, Medicationdiscountcard.com Offers Survival Tips for Those Forgoing Health Insurance Coverage in 2014
4. Pharmspective Launches Affordable Care Act eLearning for Healthcare Decision-Makers
5. HDMAs Gray: Passage Of National Pharmaceutical Traceability Legislation A Critical Accomplishment For Healthcare Industry And Patients
6. GW Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
7. LDV 2014 Harmony Mobile Womens Health On Display At RSNA
8. CVS Caremark Names Tracy Bahl as Executive Vice President, Health Plans
9. CareFusion To Acquire Vital Signs Division of GE Healthcare For $500 Million
10. ANI Pharmaceuticals To Present At Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
11. mHealth market is Expected to Reach $58.8 Billion Globally by 2020 According to Allied Market Research Projections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
Breaking Medicine News(10 mins):